menu

CME: Comprehending the PsA Agents in Late-Stage Clinical Development

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Comprehending the PsA Agents in Late-Stage Clinical Development

close
0.25 credits
15 Minutes
Comprehending the PsA Agents in Late-Stage Clinical Development
Restart
Resume
Read full article
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
Details
Presenters
Related
Comments
  • Overview

    There has been substantial progress over the last decade in understanding the origins and inflammatory progressions of psoriatic arthritis (PsA), which has led to the development of improved pharmacologic agents. While there are now a wide variety of biologics, biosimilars, and targeted treatments available, several novel agents are currently in late-stage trials and have the potential to dramatically improve care. “Comprehending the PsA Agents in Late-Stage Clinical Development” will review relevant clinical trial data and explore all the potential uses of novel investigational therapies for PsA.

  • Steering Committee

    MARINA N. MAGREY, MD
    Associate Professor of Medicine
    Case Western Reserve University School of Medicine
    Director, Arthritis Clinic and Fellowship Program
    MetroHealth Medical Center
    Cleveland, OH 

    Marina N. Magrey, MD is Associate Professor of Medicine at the Case Western Reserve University School of Medicine and the Director of the Arthritis Clinic and Fellowship Program at MetroHealth Medical Center in Cleveland, OH. She previously served as the Medical Director of the MetroHealth Beachwood Medical Center.

    Dr. Magrey studied pre-medicine at the Government College for Women in India, then completed her MBBS at the University of Kashmir. She then completed an internship and residency in the Department of Medicine, as well as a fellowship in the Division of Rheumatology, at the Cleveland Clinic.

    A member of the American College of Rheumatology, Cleveland Society of Rheumatology, Dr. Magrey serves on the Education Committee of the Spondyloarthritis Research and Treatment Network (SPARTAN). She is the invited member of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) and the Assessment of Spondyloarthritis International Society (ASAS).

    The author or co-author of numerous journal articles, book chapters, and abstracts, Dr. Magrey is also an ad-hoc reviewer for several peer-reviewed journals, including Arthritis Care and Research, Seminars in Arthritis and Rheumatism, International Journal of Rheumatic Diseases, and the Journal of Rheumatology.

    SIBA P. RAYCHAUDHURI, MD
    Chief Rheumatologist, Sacramento VAMC
    Professor, Department of Medicine/Rheumatology, Allergy, and Clinical Immunology
    University of California-Davis
    Davis, CA

    Siba P. Raychaudhuri, MD is the Chief Rheumatologist at the Sacramento VAMC and a Professor in the Department of Medicine/Rheumatology, Allergy, and Clinical Immunology at the University of California-Davis (UC-Davis) in Davis, CA. He is also the Director of the Rheumatology and Immunology Training Fellowship program at UC-Davis and teaches courses on clinical medicine, immunology, and immuno-pharmacology to medical students, immunology graduate students, and medical residents. Dr. Raychaudhuri established the Psoriasis Research Center at UC-Davis and Sacramento VAMC and has directed one of the most successful psoriasis research programs. He is also Director of the Psoriatic Disease Clinic and, at the Stanford University Medical Center, he worked on cutting-edge immune-based therapies for autoimmune diseases.

    Dr. Raychaudhuri earned his MBBS from Medical College Calcutta in India and his medical doctorate from the Post Graduate Institute of Medical Education and Research in India. He completed his postdoctoral fellowship at the Stanford University School of Medicine and Psoriasis Research Institute in Palo Alto, CA. He then completed a fellowship in rheumatology at the Stanford University School of Medicine.

    A former member of the Board of Directors of the Spondyloarthritis Research and Treatment Network, Dr. Raychaudhuri serves on the Editorial Boards of Clinical Reviews in Allergy and Immunology and the Indian Journal of Dermatology. He is also an ad-hoc reviewer for numerous peer-reviewed journals, including the New England Journal of Medicine, Journal of Investigative Dermatology, Journal of Autoimmunity, and British Journal of Dermatology. 

  • Disclosure of Conflicts of Interest

    Disclosure Statement
    The National Psoriasis Foundation (NPF) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

    All persons in a position to control the content of a continuing medical education program provided by NPF are required to disclose any relevant financial relationships with any commercial interest to NPF as well as to learners. All conflicts of interest are identified and resolved by NPF in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners. The content of this activity was vetted by an external reviewer to assure objectivity and that the activity is free of commercial bias.

    Steering Committee
    The steering committee reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

    Siba Raychaudhuri, MD: Grants/Research Support: AbbVie, Amgen, Johnson & Johnson, Lilly, Novartis, Pfizer, Sun Pharmacy; Advisory Board: Johnson & Johnson, Lilly, Novartis, Pfizer

    Marina Magrey, MD​: Consultant: Novartis; Advisory Board: Eli Lilly, Novartis; Clinical Trials: AbbVie, UCB Pharma

    Non-faculty Content Contributors
    Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

    Nicolle Rochino, PharmD, Rh; Blair St. Amand; Andi Agnew: Nothing to disclose

    FDA Disclosure
    The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

  • Target Audience

    This activity is intended for rheumatologists and others on the rheumatology care team, as these clinicians are the main care providers for patients with PsA.

  • Learning Objectives

    This program is designed to address ACGME and NAM competencies, including delivering patient-centered care and practicing evidence-based medicine.

    At the conclusion of this activity, participants should be able to:

    • Evaluate the safety and efficacy data for PsA agents in late-stage clinical development
  • Accreditation and Credit Designation Statements

    Accreditation Statement
    The National Psoriasis Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

    Designation Statement
    The National Psoriasis Foundation designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Provided by: 

    Educational Partner:

  • Commercial Support

    This activity is supported by an educational grant from Lilly.  For further information concerning Lilly grant funding visit www.lillygrantoffice.com

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    There has been substantial progress over the last decade in understanding the origins and inflammatory progressions of psoriatic arthritis (PsA), which has led to the development of improved pharmacologic agents. While there are now a wide variety of biologics, biosimilars, and targeted treatments available, several novel agents are currently in late-stage trials and have the potential to dramatically improve care. “Comprehending the PsA Agents in Late-Stage Clinical Development” will review relevant clinical trial data and explore all the potential uses of novel investigational therapies for PsA.

  • Steering Committee

    MARINA N. MAGREY, MD
    Associate Professor of Medicine
    Case Western Reserve University School of Medicine
    Director, Arthritis Clinic and Fellowship Program
    MetroHealth Medical Center
    Cleveland, OH 

    Marina N. Magrey, MD is Associate Professor of Medicine at the Case Western Reserve University School of Medicine and the Director of the Arthritis Clinic and Fellowship Program at MetroHealth Medical Center in Cleveland, OH. She previously served as the Medical Director of the MetroHealth Beachwood Medical Center.

    Dr. Magrey studied pre-medicine at the Government College for Women in India, then completed her MBBS at the University of Kashmir. She then completed an internship and residency in the Department of Medicine, as well as a fellowship in the Division of Rheumatology, at the Cleveland Clinic.

    A member of the American College of Rheumatology, Cleveland Society of Rheumatology, Dr. Magrey serves on the Education Committee of the Spondyloarthritis Research and Treatment Network (SPARTAN). She is the invited member of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) and the Assessment of Spondyloarthritis International Society (ASAS).

    The author or co-author of numerous journal articles, book chapters, and abstracts, Dr. Magrey is also an ad-hoc reviewer for several peer-reviewed journals, including Arthritis Care and Research, Seminars in Arthritis and Rheumatism, International Journal of Rheumatic Diseases, and the Journal of Rheumatology.

    SIBA P. RAYCHAUDHURI, MD
    Chief Rheumatologist, Sacramento VAMC
    Professor, Department of Medicine/Rheumatology, Allergy, and Clinical Immunology
    University of California-Davis
    Davis, CA

    Siba P. Raychaudhuri, MD is the Chief Rheumatologist at the Sacramento VAMC and a Professor in the Department of Medicine/Rheumatology, Allergy, and Clinical Immunology at the University of California-Davis (UC-Davis) in Davis, CA. He is also the Director of the Rheumatology and Immunology Training Fellowship program at UC-Davis and teaches courses on clinical medicine, immunology, and immuno-pharmacology to medical students, immunology graduate students, and medical residents. Dr. Raychaudhuri established the Psoriasis Research Center at UC-Davis and Sacramento VAMC and has directed one of the most successful psoriasis research programs. He is also Director of the Psoriatic Disease Clinic and, at the Stanford University Medical Center, he worked on cutting-edge immune-based therapies for autoimmune diseases.

    Dr. Raychaudhuri earned his MBBS from Medical College Calcutta in India and his medical doctorate from the Post Graduate Institute of Medical Education and Research in India. He completed his postdoctoral fellowship at the Stanford University School of Medicine and Psoriasis Research Institute in Palo Alto, CA. He then completed a fellowship in rheumatology at the Stanford University School of Medicine.

    A former member of the Board of Directors of the Spondyloarthritis Research and Treatment Network, Dr. Raychaudhuri serves on the Editorial Boards of Clinical Reviews in Allergy and Immunology and the Indian Journal of Dermatology. He is also an ad-hoc reviewer for numerous peer-reviewed journals, including the New England Journal of Medicine, Journal of Investigative Dermatology, Journal of Autoimmunity, and British Journal of Dermatology. 

  • Disclosure of Conflicts of Interest

    Disclosure Statement
    The National Psoriasis Foundation (NPF) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

    All persons in a position to control the content of a continuing medical education program provided by NPF are required to disclose any relevant financial relationships with any commercial interest to NPF as well as to learners. All conflicts of interest are identified and resolved by NPF in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners. The content of this activity was vetted by an external reviewer to assure objectivity and that the activity is free of commercial bias.

    Steering Committee
    The steering committee reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

    Siba Raychaudhuri, MD: Grants/Research Support: AbbVie, Amgen, Johnson & Johnson, Lilly, Novartis, Pfizer, Sun Pharmacy; Advisory Board: Johnson & Johnson, Lilly, Novartis, Pfizer

    Marina Magrey, MD​: Consultant: Novartis; Advisory Board: Eli Lilly, Novartis; Clinical Trials: AbbVie, UCB Pharma

    Non-faculty Content Contributors
    Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

    Nicolle Rochino, PharmD, Rh; Blair St. Amand; Andi Agnew: Nothing to disclose

    FDA Disclosure
    The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

  • Target Audience

    This activity is intended for rheumatologists and others on the rheumatology care team, as these clinicians are the main care providers for patients with PsA.

  • Learning Objectives

    This program is designed to address ACGME and NAM competencies, including delivering patient-centered care and practicing evidence-based medicine.

    At the conclusion of this activity, participants should be able to:

    • Evaluate the safety and efficacy data for PsA agents in late-stage clinical development
  • Accreditation and Credit Designation Statements

    Accreditation Statement
    The National Psoriasis Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

    Designation Statement
    The National Psoriasis Foundation designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Provided by: 

    Educational Partner:

  • Commercial Support

    This activity is supported by an educational grant from Lilly.  For further information concerning Lilly grant funding visit www.lillygrantoffice.com

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 12/1/20